|
|
|
| Efficacy and safety of ergometrine, hemabate and oxytocin for preventing and treating vaginal delivery women with postpartum hemorrhage because of uterine inertia |
| 1.Beijing Asian games village beauty and children's hospital,Beijing,100016；2.The first affiliated hospital of tsinghua university |
|
|
|
|
Abstract Objective: To analyze the clinical efficacy and safety of ergometrine, postpartum hemorrhage (hemabate) and oxytocin for preventing and treating vaginal delivery women with postpartum hemorrhage (PPH) because of uterine inertia. Methods: The data of 972 vaginal delivery women with PPH because of uterine inertia from March 2015 to May 2018 were retrospective analyzed. All included women were divided into group A, group B and group C. 324 women in group A were given intramuscular injected with 0.2mg ergoxin immediately after delivery, 324 women in group B were given 10U oxytocin cervical injection and oxytocin intravenously injected with 0.03U/min (0.01U:1ml sodium chloride injection as diluent), and 324 women in group C were given hemabate 250μ g cervical injection. The amount of postpartum hemorrhage and hemostatic time, hemodynamic parameters, and coagulation function index of women in the three groups before delivery and 24 hours after delivery were recorded. Results: The amount of hemorrhage of women in 2 hour or 24 hours after delivery in group B was significant higher than that of women in group A and group C (P<0.05), but there was no significant difference in the amount of hemorrhage of women in 2 hour or 24 hours after delivery between group A and group C (P>0.05). The hemostatic effective rate of women in group A and C was 94.1% and 100%, which was significant higher than that (82.6%) of women in group B (P<0.05). There were no significant difference in hemodynamic parameters, coagulation function index, and hemoglobin level of women before delivery and 24 hours after delivery among the three groups (P>0.05). The adverse reaction rate of women in group A was 16.1%, which was significant higher than that (4.0% or 4.9%) of women in group B or group C (P<0.05), but there was no significant difference between group B and group C (P>0.05). Conclusion: As for preventing PPH and hemostasis, ergoxin and hemabate have high effectiveness, but oxytocin has slightly less effectiveness because of drug sensitivity and mild limitation of oxytocin. The safety of hemabate and oxytocin is better, ergoxin maybe increase the adverse reactions of women. So hemabate is the first choice to prevent PPH by uterine inertia, which’s hemostasis is more advantageous.
|
|
|
|
|
|
|
|
|
